Hsp90 as a therapeutic target in patients with oesophageal carcinoma

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 3, 2010, Pages 317-328

  Ekman, Simon ^a   Bergqvist, Michael ^a   Tell, Roger ^a   Bergstrm, Stefan ^b   Lennartsson, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Centre for RF Measurement Technology   (Sweden)

Author keywords

17 AAG; Epidermal growth factor; Geldanamycin; Hsp90; Oesophageal cancer

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; ABI 010; ABL 010; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; AT 13387; AUY 922; BCR ABL PROTEIN; BORTEZOMIB; CISPLATIN; CNF 2024; DOCETAXEL; GELATINASE A; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; HSP 990; IMATINIB; MPC 3100; PROTEIN KINASE LCK; PROTEIN P53; RAF PROTEIN; SNX 5422; STA 9090; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 888;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BINDING SITE; BREAST CANCER; CANCER THERAPY; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRY EYE; ENZYME ACTIVITY; ESOPHAGUS CARCINOMA; FATIGUE; GASTROINTESTINAL SYMPTOM; GENETIC VARIABILITY; HUMAN; HYPERGLYCEMIA; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MOLECULAR MECHANICS; MULTIPLE MYELOMA; NAUSEA AND VOMITING; ONCOGENE; OVERALL SURVIVAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; ESOPHAGEAL NEOPLASMS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PROGNOSIS; SURVIVAL RATE;

EID: 77149141379     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728221003621278     Document Type: Review

References (97)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-2252
2. Sykes AJ, Burt PA, Slevin NJ, et al. Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol 1998;48:15-21
3. Panettiere FJ, Leichman LP, Tilchen EJ, et al. Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: final report on a Southwest Oncology Group study. Cancer Treat Rep 1984;68:1023-1024
4. Ravry MJ, Moore MR, Omura GA, et al. Phase II evaluation of cisplatin in squamous carcinoma of the esophagus: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1985;69:1457-1458
5. Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-1220
6. Wadler S, Haynes H, Beitler JJ, et al. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. Cancer 1996;78:30-34
7. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006:CD002092: first published online: 25 January 2006 in Issue 1, 2006. Last assessed as up-to-date: 30 October 2005, doi: 10.1002/14651858.CD002092.pub2
8. Arnott SJ, Duncan W, Gignoux M. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005:CD001799: published online: 19 October 2005 in Issue 4, 2005. Last assessed as up-to-date: 30 March 2009, doi: 10.1002/14651858. CD001799.pub2
9. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-234
10. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
11. Lordick F, Ott K, Krause B-J, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797-805
12. Carolina P, Hagop K, Jorge EC. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 2009;84:287-293
13. Zhang M, Boter M, Li K, et al. Structural and functional coupling of Hsp90- and Sgt1-centred multi-protein complexes. EMBO J 2008;27:2789-2798
14. Zhang M, Windheim M, Roe SM, et al. Chaperoned ubiquitylation-crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex. Mol Cell 2005;20:525-538
15. Shiau AK, Harris SF, Southworth DR, et al. Structural analysis of E. coli HSP90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell 2006;127:329-340
16. Mclaughlin SH, Smith HW, Jackson SE. Stimulation of the weak ATPase activity of human Hsp90 by a client protein. J Mol Biol 2002;315:787-798
17. Siligardi G, Panaretou B, Meyer P, et al. Regulation of Hsp90 ATPase activity by the Co-chaperone Cdc37p/p50cdc37. J Biol Chem 2002;277:20151-20159 (Pubitemid 34967306)
18. Martinez-Ruiz A, Villanueva L, Gonzalez De Orduña C, et al. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc Natl Acad Sci USA 2005;102:8525-8530
19. Scroggins BT, Robzyk K, Wang D, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 2007;25:151-159
20. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-513
21. Yang Y, Rao R, Shen J, et al. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 2008;68:4833-4842
22. Duval M, Boeuf FL, Huot J, et al. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial no synthase. Mol Biol Cell 2007;18:4659-4668
23. Erkeller-Yüksel FM, Isenberg DA, Dhillon VB, et al. Surface expression of heat shock protein 90 by blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun 1992;5:803-814
24. Sumizawa T, Igisu H. Release of heat shock proteins from human neuroblastoma cells exposed to acrylamide. J Toxicol Sci 2008;33:117-122
25. Sidera K, Samiotaki M, Yfanti E, et al. Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system. J Biol Chem 2004;279:45379-45388
26. Eustace Bk T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for HSP90alpha in cancer cell invasiveness. Nat Cell Biol 2004;6:507-514
27. Tsutsumi S, Scroggins B, Koga F, et al. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 2007;27:2478-2487
28. Sidera K, Gaitanou M, Stellas D, et al. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 2008;283:2031-2041
29. Hartson SD, Ottinger EA, Huang W, et al. Modular folding and evidence for phosphorylation-induced stabilization of an HSP90-dependent kinase. J Biol Chem 1998;273:8475-8482
30. Yang S, Qu S, Perez-Tores M, et al. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res 2006;66:6990-6997
31. Wrighton KH, Lin X, Feng X-H. Critical regulation of TGFbeta signaling by Hsp90. Proc Natl Acad Sci USA 2008;105:9244-9249
32. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000;97:10832-10837
33. Stancato LF, Chow YH, Hutchison KA, et al. Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J Biol Chem 1993;268:21711-21716
34. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000;11:355-360
35. Kimura Y, Rutherford SL, Miyata Y, et al. Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev 1997;11:1775-1785
36. Smith JR, Clarke PA, De Billy E, et al. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 2008;28:157-169
37. Vaughan CK, Gohlke U, Sobott F, et al. Structure of an Hsp90-Cdc37-Cdk4 Complex. Mol Cell 2006;23:697-707
38. Pashtan I, Tsutsumi S, Wang S, et al. Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition. Cell Cycle 2008;7:2936-2941
39. Roe SM, Prodromou C, O'brien R, et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999;42:260-266
40. Prodromou C, Roe SM, O'brien R, et al. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65-75
41. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271:22796-22801
42. Smith V, Sausville EA, Camalier RF, et al. Comparison of 17-dimethylaminoethylamino- 17-demethoxy-geldanamycin (17DMAG) and 17-allylamino- 17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005;56:126-137
43. Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006;103:17408-17413
44. Mccollum AK, Teneyck CJ, Stensgard B, et al. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res 2008;68:7419-7427
45. Guo W, Reigan P, Siegel D, et al. Formation of 17-allylamino- demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H: quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 2005;65:10006-10015
46. Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-2860
47. Lundgren K, Zhang H, Brekken J, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009;8:921-929
48. Cheung K-MJ, Matthews TP, James K, et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005;15:3338-3343
49. Sharp SY, Prodromou C, Boxall K, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 2007;6:1198-1211
50. Zhang T, Hamza A, Cao X, et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008;7:162-170
51. Marina F, Silvia H, Zocchi MR, et al. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992;51:613-619
52. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-410
53. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792 (Pubitemid 40271173)
54. Shimamura T, Li D, Ji H, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008;68:5827-5838
55. Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 2009;106:8368-8373
56. Kitano H. Cancer robustness: tumour tactics. Nature 2003;426:125
57. Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006;6:1205-1214
58. Bagatell R, Gore L, Egorin MJ, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17- demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 2007;13:1783-1788
59. Banerji U, Affolter A, Judson I, et al. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 2008;7:737-739
60. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-1087
61. Nowakowski GS, Mccollum AK, Ames MM, et al. A Phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087-6093
62. Ramanathan RK, Egorin MJ, Eiseman JL, et al. Phase I and pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 2007;13:1769-1774
63. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-3391
64. Weigel BJ, Blaney SM, Reid JM, et al. A Phase I study of 17-allylaminogeldanamycin in relapsed/ refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res 2007;13:1789-1793
65. Solit DB, Osman I, Polsky D, et al. Phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008;14:8302-8307
66. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-1893
67. Ronnen EA, Kondagunta GV, Ishill N, et al. A phase II trial of 17-(Allylamino)-17- demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006;24:543-546
68. Eiseman JL, Lan J, Lagattuta TF, et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino) ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 2005;55:21-32
69. Smith V, Sausville EA, Camalier RF, et al. Comparison of 17-dimethylaminoethylamino-17- demethoxy-geldanamycin (17DMAG) and 17-allylamino-17- demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005;56:126-137
70. Shadad FN, Ramanathan RK. 17-dimethylaminoethylamino- 17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a Phase I study. Clin Lymphoma Myeloma 2006;6:500-501
71. Pacey SC, Wilson R, Walton M, et al. A phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours. J Clin Oncol 2009;27 (Suppl):abstract 3534
72. Ge J, Normant E, Porter JR, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 2006;49:4606-4615
73. Riely GJ, Stoller R, Egorin M, et al. A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel. J Clin Oncol 2009;27 (Suppl):abstract 3547
74. Sequist LV, Gettinger S, Natale R, et al. A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. J Clin Oncol 2009;27 (Suppl):abstract 8073
75. Macrae C, Richardson G, Walker J, et al. Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: results from two independent phase I trials in patients with advanced cancer. J Clin Oncol 2009;27 (Suppl):abstract e14539
76. Sessa C, Sharma SK, Britten CD, et al. A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2009;27(Suppl):abstract 3532
77. Ide S, Motwani M, Jensen MR, et al. Pharmacodynamics and pharmacokinetics of AUY922 in a phase I study of solid tumor patients. J Clin Oncol 2009;27 (Suppl):abstract 3533
78. Mitsiades CS, Mitsiades NS, Mcmullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092-1100
79. Richardson PG, Chanan-Khan A, Lonial S, et al. Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: final results of a phase I/II study. J Clin Oncol 2009;27 (Suppl):abstract 8503
80. Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004;3:51-60
81. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004;82:488-499
82. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-217
83. Doak SH, Jenkins GJS, Parry EM, et al. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression. Mutat Res Fundam Mol Mech Mutagenesis 2004;547:133-144
84. Ostrowski J, Mikula M, Karczmarski J, et al. Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics. J Mol Med 2007;85:733-743
85. Faried A, Sohda M, Nakajima M, et al. Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma. Eur J Cancer 2004;40:2804-2811
86. Wu X, Wanders A, Wardega P, et al. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17- demethoxygeldanamycin. Br J Cancer 2009;100:334-343
87. Burkitt M, Magee C, O'connor D, et al. Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition. Mol Carcinog 2007;46:466-475
88. Ogata M, Naito Z, Tanaka S, et al. Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nippon Med Sch 2000;67:177-185
89. Pick E, Kluger Y, Giltnane JM, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007;67:2932-2937
90. Thierry L, Watson RWG, Vincent M, et al. Heat shock proteins HSP27, HSP60, HSP70, and HSP90. Cancer 2003;98:970-977
91. Li C-F, Huang W-W, Wu J-M, et al. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors. Clin Cancer Res 2008;14:7822-7831
92. Liu XL, Xiao B, Yu ZC, et al. Down-regulation of Hsp90 could change cell cycle distribution and increase drug sensitivity of tumor cells. World J Gastroenterol 1999;5:199-208
93. Matsumoto Y, Machida H, Kubota N. Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin. J Radiat Res 2005;46:215-221
94. Bull EEA, Dote H, Brady KJ, et al. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin. Clin Cancer Res 2004;10:8077-8084
95. Noguchi M, Yu D, Hirayama R, et al. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin. Biochem Biophys Res Commun 2006;351:658-663 [Epub ahead of print]
96. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007;17:2-9
97. Chang DT, Chapman C, Shen J, et al. Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis. Am J Clin Oncol 2009;32(4):405-410